# A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

> **NCT06163430** · PHASE1,PHASE2 · RECRUITING · sponsor: **Terns, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** TERN-701

## Key facts

- **NCT ID:** NCT06163430
- **Lead sponsor:** Terns, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-26
- **Primary completion:** 2029-11-30
- **Final completion:** 2030-05-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06163430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06163430, "A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06163430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*